Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG9924 extension study with methotrexate in rheumatoid arthritis
2007-000733-19Phase 2Terminated
- Sponsor
- Biogen
- Start
- Jun 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of baminercept and methotrexate in rheumatoid arthritis (RA), sponsored by Biogen. Primary endpoint: Safety and durability of efficacy response. Started Jun 2007; status: terminated.
02
Drugs
baminerceptmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-000733-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000733-19.